[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Crinetics Pharmaceuticals Inc (CRNX)

Crinetics Pharmaceuticals Inc (CRNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,985,827
  • Shares Outstanding, K 106,065
  • Annual Sales, $ 7,700 K
  • Annual Income, $ -465,320 K
  • EBIT $ -548 M
  • EBITDA $ -560 M
  • 60-Month Beta 0.12
  • Price/Sales 1,168.01
  • Price/Cash Flow N/A
  • Price/Book 7.54

Options Overview Details

View History
  • Implied Volatility 5.58% (-11.67%)
  • Historical Volatility 2.17%
  • IV Percentile 3%
  • IV Rank 1.20%
  • IV High 95.22% on 12/17/25
  • IV Low 4.49% on 08/17/26
  • Expected Move (DTE 2) 0.51 (0.60%)
  • Put/Call Vol Ratio 4.44
  • Today's Volume 98
  • Volume Avg (30-Day) 572
  • Put/Call OI Ratio 0.63
  • Today's Open Interest 27,075
  • Open Int (30-Day) 21,544
  • Expected Range 84.24 to 85.26

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-1.20
  • Number of Estimates 6
  • High Estimate $-0.95
  • Low Estimate $-1.34
  • Prior Year $-1.38
  • Growth Rate Est. (year over year) +13.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
83.47 +1.55%
on 07/31/26
84.79 -0.04%
on 08/18/26
+0.90 (+1.07%)
since 07/17/26
3-Month
32.30 +162.41%
on 06/02/26
84.79 -0.04%
on 08/18/26
+49.82 (+142.59%)
since 05/19/26
52-Week
28.73 +195.02%
on 08/21/25
84.79 -0.04%
on 08/18/26
+55.33 (+188.01%)
since 08/19/25

Most Recent Stories

More News
Are DSGR, HLX, ATAI, CRNX Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

ATAI : 7.32 (+0.41%)
HLX : 10.42 (+0.39%)
CRNX : 84.76 (+0.05%)
DSGR : 34.83 (+0.45%)
Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Crinetics Pharmaceuticals...

CRNX : 84.76 (+0.05%)
VRTX : 546.26 (+3.42%)
Are UTZ, VEEE, CRNX Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

CRNX : 84.76 (+0.05%)
VEEE : 10.04 (-6.60%)
UTZ : 14.19 (+0.21%)
SHAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger--CRNX, PSBQ, UTZ, and VEEE

NEW YORK , Aug. 6, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders...

CRNX : 84.76 (+0.05%)
VEEE : 10.04 (-6.60%)
PSBQ : 52.4900 (-0.13%)
UTZ : 14.19 (+0.21%)
Are ACA, CRNX, LEG Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

CRNX : 84.76 (+0.05%)
ACA : 145.28 (-0.05%)
LEG : 9.57 (+2.24%)
Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

      Announced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billion, or Approximately $8.8B Net of Estimated Cash Acquired        PALSONIFY®...

CRNX : 84.76 (+0.05%)
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger--ACA, CRNX, LEG, and LPSN

NEW YORK , Aug. 3, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for...

CRNX : 84.76 (+0.05%)
LPSN : 2.87 (+0.88%)
ACA : 145.28 (-0.05%)
LEG : 9.57 (+2.24%)
Are UTZ, CRNX, SOLS Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

SOLS : 58.30 (-2.98%)
CRNX : 84.76 (+0.05%)
UTZ : 14.19 (+0.21%)
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--CRNX, SLP, NCSM, and PASG

NEW YORK , July 23, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for...

PASG : 4.50 (-0.44%)
CRNX : 84.76 (+0.05%)
SLP : 18.36 (unch)
NCSM : 50.80 (+0.67%)
Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

CRNX : 84.76 (+0.05%)
VEEE : 10.04 (-6.60%)
NXTC : 6.89 (+3.61%)
TCBK : 56.17 (-0.93%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 80%. The market is in extreme overbought territory. Beware of a trend reversal.

See More Share

Business Summary

CRINETICS PHARMACEUTICALS is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. CRINETICS PHARMACEUTICALS is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 84.91
2nd Resistance Point 84.85
1st Resistance Point 84.79
Last Price 84.76
1st Support Level 84.66
2nd Support Level 84.60
3rd Support Level 84.54

See More

52-Week High 84.79
Last Price 84.76
Fibonacci 61.8% 63.38
Fibonacci 50% 56.76
Fibonacci 38.2% 50.15
52-Week Low 28.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.